Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27696295 | 0.78 | MAOB (0.44) | PTGS1PTGS2PARP1LMNAHSD17B10 | |
| SCHEMBL113556 | 0.78 | PARP1 (0.42) | PARP1LMNAL3MBTL1ESR1ESR2 | |
| SCHEMBL114458 | 0.78 | MAPK1 (0.44) | PARP1CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL113493 | 0.78 | SYK (0.44) | PTGS1PTGS2PARP1GAAL3MBTL1 | |
| SCHEMBL112405 | 0.78 | PARP1 (0.36) | PTGS1PTGS2PARP1LMNAALDH1A1 | |
| SCHEMBL23501351 | 0.78 | MAPK1 (0.44) | PARP1CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL18826411 | 0.77 | ALDH1A1 (0.56) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL18826414 | 0.77 | ALDH1A1 (0.56) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL1574429 | 0.77 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL3272099 | 0.76 | RXRA (0.53) | PARP1ALDH1A1RXRARXRBRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2018-08-02 | — | — | US | disclosed |
| US-9951059-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2017-08-17 | — | — | US | disclosed |
| US-20160272589-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2016-09-22 | — | — | US | disclosed |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8716310-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | AKR1C3 1082/4885AKR1C2 1047/4885PTGS1 173/4885 |
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | AKR1C3 1082/4885AKR1C2 1047/4885PTGS1 173/4885 |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | AKR1C3 1082/4885AKR1C2 1047/4885PTGS1 173/4885 |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | AKR1C3 1082/4885AKR1C2 1047/4885PTGS1 173/4885 |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | AKR1C3 1082/4885AKR1C2 1047/4885PTGS1 173/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | AKR1C3 1963/4885AKR1C2 1957/4885PTGS1 1230/4885 |
| US-20160272589-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | AKR1C3 1082/4885AKR1C2 1047/4885PTGS1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.